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Abstract
Sézary syndrome (SS) is a heterogeneous leukemic subtype of cutaneous T-cell lymphoma (CTCL) with generalized
erythroderma, lymphadenopathy, and a poor prognosis. Advanced disease is invariably associated with severe
immune dysregulation and the majority of patients die from infectious complications caused by microorganisms such
as, Staphylococcus aureus, rather than from the lymphoma per se. Here, we examined if staphylococcal enterotoxins
(SE) may shape the phenotype of malignant SS cells, including expression of the regulatory T-cell-associated marker
FOXP3. Our studies with primary and cultured malignant cells show that SE induce expression of FOXP3 in malignant
cells when exposed to nonmalignant cells. Mutations in the MHC class II binding domain of SE-A (SEA) largely block
the effect indicating that the response relies at least in part on the MHC class II-mediated antigen presentation.
Transwell experiments show that the effect is induced by soluble factors, partly blocked by anti-IL-2 antibody, and
depends on STAT5 activation in malignant cells. Collectively, these findings show that SE stimulate nonmalignant cells
to induce FOXP3 expression in malignant cells. Thus, differences in exposure to environmental factors, such as
bacterial toxins may explain the heterogeneous FOXP3 expression in malignant cells in SS.
Introduction
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous
group of non-Hodgkin T-cell lymphomas with primary
involvement of the skin. Sézary syndrome (SS) is an
especially aggressive subtype of CTCL characterized by
the presence of leukemic cells in the blood, generalized
erythroderma, lymphadenopathy, and a median survival
of only 3 years1–3. The etiology is unknown and recent
attempts to identify recurrent key driver mutations have
had limited success, while chromosomal instability and
major genetic alterations are commonly seen4–10.
Importantly, SS is a heterogeneous disease and we
recently reported that malignant cells also display a pro-
nounced heterogeneity at the single-cell level in individual
SS patients11.
A defining feature of SS is that advanced disease is
associated with a distinctive tumor microenvironment
dominated by TH2 cytokines
2,12 and a general absence of
TH1 cytokines, such as IFN-γ and IL-12 (refs.
13–16).
Expression of the immunosuppressive cytokines TGF-β
and IL-10 has also been reported, and is likely caused by
deregulated JAK/STAT3 and NFκB signaling17–20. SS
patients display severe functional defects in neutrophils,
NK−, and dendritic cells, effectively impairing cellular
immunity16,21,22. Notably, Berger et al. reported that
immature dendritic cells in vitro induced a regulatory
phenotype in malignant cells with expression of the IL-2
receptor subunit alpha (CD25) and FOXP3 (ref. 23). This
observation made the authors hypothesize that CTCL
involved malignant proliferation of regulatory T (Treg)
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cells23. Expression of FOXP3 in malignant cells is con-
spicuous as it is a major transcription factor essential in
driving the differentiation of Tregs. However, it has been a
matter of controversy whether or not malignant cells
express FOXP3 and display a Treg phenotype in vivo, and
very different frequencies of FOXP3-positive malignant
cells have been reported in different cohorts of SS
patients24–29. Moreover, malignant cells may even display
a heterogeneous FOXP3 expression pattern at the single-
cell level in an individual patient30 or in skin lesions, as
judged from immunohistochemistry staining of cells with
neoplastic morphology17.
As advanced SS is associated with an increasingly
impaired immune defense, SS patients have an increased
risk of contracting infections31 and the majority of
patients with advanced disease die from infection rather
than from the lymphoma per se32,33. Notably, severe
bacterial infections are almost exclusively seen long after
the diagnosis has been established34. Since malignant cells
induce structural changes in the skin leading to impair-
ment of the skin barrier in 3D in vitro skin35, it is likely
that lymphoma-induced skin barrier defects play an
important role in the increased susceptibility to bacterial
infections in SS.
Staphylococcus aureus is a very prevalent pathogen in
SS, and accounts for much morbidity and mortality due to
recurrent or chronic skin infections, sepsis, pneumonia,
and intra-abdominal infections32,33,36,37. Some studies
have also implicated staphylococcal enterotoxins (SE)
from S. aureus in the pathogenesis of CTCL. SE can
induce activation of STAT3 in malignant cells and
secretion of cytokines, such as IL-10 (refs. 20,38). Other
previous studies have shown that clearing S. aureus
infections with antibiotics is associated with clinical
improvement and a decrease in the tumor burden in
CTCL patients (reviewed in ref. 39). We recently
demonstrated that eradication of S. aureus in patients
with advanced CTCL by systemic treatment with anti-
biotics induced a decrease in the malignant T-cell clone,
diminished skin inflammation, and led to the clinical
improvement in patients with advanced CTCL, providing
the first evidence that S. aureus can fuel malignant T-cell
proliferation in vivo40. The present study was undertaken
to determine whether and how clinical isolates, and SE
modulate FOXP3 expression in malignant cells from SS
patients.
Materials and methods
Antibodies and reagents
IL-2- and IL-15-blocking antibodies were purchased
from R&D Systems (Minneapolis, MN). Erk1/2 anti-
bodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). FOXP3 (236 A/E7) for western blot-
ting was from eBioscience (San Diego, CA, USA).
Fluorochrome-conjugated CD3, CD4, CD7, CD8, CD19,
CD25, CD26, pY-STAT5, FOXP3, and respective
fluorochrome-conjugated isotype control Abs used for
FACS were provided by Biolegend (San Diego, CA,
USA) and BD Biosciences (San Jose, CA, USA). The SE
(staphylococcal enterotoxin A (SEA), SEB, SEC2, SED,
and SEI) from Toxin Technology (Sarasota, FL, USA),
Propidium iodide was from Thermo Fisher Scientific
(Waltham, MA, USA), and Fixable Viability Stain Dye
eFluor780 from eBioscience. SEA mutants were gener-
ously provided by Active Biotech (Lund, Sweden).
Patients and isolation of S. aureus bacteria
Malignant and nonmalignant cells were isolated from
the blood of patients diagnosed with SS in accordance
with the World Health Organization/European Organi-
zation for Research and Treatment of Cancer classifica-
tion41. See Supplementary Table 1 for patient
characteristics. Malignant cells typically lack the expres-
sion of cell surface marker CD26 and/or CD7 (ref. 2).
Accordingly, T cells were identified as malignant (CD4+,
CD7dim/−, and CD26dim/−) and nonmalignant (CD4
+/CD7+, and CD26+). Bacterial isolates were collected
from CTCL patients using swabs wetted with 0.1% Triton
X-100 in 0.075M phosphate buffer, transferred to Stuart
transport medium, and cultivated on blood agar overnight
at 37 °C at 5% carbon dioxide.
In accordance with the Declaration of Helsinki, all
samples were obtained with informed consent after
approval by the Committee on Health Research Ethics (H-
16025331).
Cell lines
The malignant T-cell line SeAx and the nonmalignant
T-cell line, MF1850, were established from patients
diagnosed with CTCL (ref. 42), and cultured in media
supplemented with 10% human serum (HS medium) and
IL-2. Cell lines were tested for mycoplasma contamina-
tion. Prior to experimental setup, the CTCL cell lines
were starved overnight in HS medium without IL-2.
Detection of SE in bacterial isolate supernatants
The presence of SE in bacterial cultures was examined
using the RIDASCREEN SET A, B, C, D, E kit (R-Bio-
pharm, Darmstadt, Germany), with a toxin detection limit
of 0.25 ng/mL and in accordance with the manufacturer’s
instructions.
RNA purification, complementary DNA synthesis, and qPCR
Total cellular RNA was purified and reverse transcribed
into complementary DNA as previously described43.
Quantitative polymerase chain reaction (qPCR) was per-
formed using the TaqMan assay from Thermo Fisher
Scientific in accordance with the manufacturer’s
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instructions, and the samples were analyzed on a Light-
Cycler480 II instrument (Roche).
Cell isolation, flow cytometry, and cell sorting
Peripheral blood mononuclear cells (PBMCs) were
isolated from the blood of SS patients by lymphoprep
density-gradient centrifugation (Stemcell technologies)
and1 used directly for flow cytometric analysis2, cultured
in HS medium with phosphate-buffered saline (PBS) or
SE, or3 sorted by FACS using FACSAria-II (BD Bios-
ciences) into populations of malignant and nonmalignant
cells based on CD4 and CD26 surface expression, and
then mono- or co-cultured in HS medium with PBS or SE.
Purity of the sorted malignant and nonmalignant cells was
99% and 95%, respectively. In experiments in which co-
cultured SeAx and MF1850 cells were sorted, the SeAx
cells were stained prior to culture with 1 uM carboxy-
fluorescein succinimidyl ester (CFSE). The CFSE-positive
(SeAx) and CFSE-negative (MF1850) cells were sorted by
FACSAria resulting in a purity of 98%. Data acquisition
and flow cytometric analysis were performed on LSR
Fortessa flow cytometers (BD Biosciences) using FlowJo
software (Tree Star, Ashland, OR).
Western blotting
Cells were rapidly pelleted and lysed in ice-cold lysis
buffer (1% NP-40, 20 mM TRIS-HCl pH 8.0, 140mM
NaCl, 10% glycerol, and the following inhibitors: 1 mM
phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 10mM
NaF, 1 mM iodioacetamide, 5 mM ethylenediaminete-
traacetic acid, and 7.5 μg/ml aprotinin) for 30 min on ice.
Total cell lysates were boiled in reducing sodium dodecyl
sulfate (SDS) sample buffer and subjected to
SDS–polyacrylamide gel electrophoresis followed by
electrophoretic transfer to a nitrocellulose (NC) mem-
brane. Afterward, the NC membrane was blocked with 3%
milk in PBS-T for 1 h and then incubated with primary
Abs overnight. Subsequently, the NC membrane was
incubated with HRP-conjugated secondary Abs for 1 h
(DAKO). Blots were evaluated using enhanced chemilu-
minescence according to the manufacturer’s instructions.
To ensure equal loading, the total protein concentration
of each sample was determined by Bio-Rad Protein Assay
(Bio-Rad; Hercules, CA, USA).
Transient transfections
A total of 2 × 106 cells per sample were transfected
with siRNA against STAT5 or nontargeting control
(ON-TARGETplus SMARTpool; Thermo Scientific,
Lafayette, CO, USA). Pellets were resuspended in
100 mL of Transfection solution (Ingenio Electropora-
tion Solution; Mirus Bio, Madison, WI, USA) in the
presence of 0.25 mM of the respective siRNAs, and
transfected with an Amaxa Nucleofector (Lonza,
Cologne, Germany).
Statistics
For statistical analysis, a two-tailed Student’s t-test with
a significance level of P= 0.05 was applied. Error bars
represent standard error of the mean.
Results
SE induce FOXP3 and CD25 upregulation in malignant cells
Prior to flow cytometric analysis for FOXP3 and CD25
expression, the malignant SS T-cell line SeAx, was cultured
with and without a nonmalignant T-cell line (MF1850) in
the presence or absence of supernatants from two clinical S.
aureus isolates that were either positive or negative for SE.
Figure 1a shows FOXP3 and CD25 expression in malignant
cells, following 24 h of monoculture (Fig. 1a, upper row)
and co-culture with nonmalignant cells (Fig. 1a, lower row)
with SE-positive (SA sup A) and -negative (SA sup B)
supernatants, and PBS as control (Fig. 1a). Strikingly, the
SE-positive supernatant induced a profound upregulation of
FOXP3 and CD25 expression by malignant cells co-
cultured with nonmalignant cells (Fig. 1a, lower, middle).
In contrast, the SE-positive supernatant had little effect on
malignant cells grown in monoculture (Fig. 1a, upper,
middle), in agreement with our published observations20,38.
A similar expression pattern was obtained after 3 days of
culture with S. aureus supernatants (Fig. 1b). Applying SEA
yielded essentially identical results (Fig. 1c). Importantly,
SEA induced a very high co-expression of FOXP3 and
CD25 in malignant cells co-cultured with nonmalignant
cells (Fig. 1c, upper right), as compared to co-cultures
without SEA, and monocultures with and without SEA (Fig.
1c, upper left). In nonmalignant cells, SEA induced strong
CD25 expression, but only weak FOXP3 expression when
co-cultured with malignant cells (Fig. 1c, lower right),
whereas nonmalignant cells in monoculture responded to
SEA with a moderate upregulation of FOXP3, when com-
pared to cultures without SEA (Fig. 1c, lower middle and
left). FOXP3/CD25 co-expression was considerably higher
in malignant cells, when compared to nonmalignant cells in
SEA-stimulated co-cultures (Fig. 1c, upper versus lower
right). Taken together, malignant cells can be induced by SE
to express high levels of both CD25 and FOXP3, if non-
malignant cells are present. These findings support a model
where SE induces crosstalk between malignant and non-
malignant cells, which in turn affects the phenotype of the
malignant cells. These findings prompted us to investigate
whether SE could also stimulate FOXP3 expression in pri-
mary malignant cells from SS patients, following co-culture
with nonmalignant cells.
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Fig. 1 SE induce FOXP3 and CD25 upregulation in malignant cells. a Malignant cells (SeAx) were cultured alone or in the presence of nonmalignant
cells (MF1850) with vehicle (PBS), staphylococcal enterotoxins (SE), or with either a SE-positive (SA sup A) or SE-negative (SA sup B) supernatant from clinical S.
aureus isolates for 24h. Contour plots show gated malignant cells. bMalignant cells (SeAx) were cultured alone or in the presence of nonmalignant cells (MF1850)
with vehicle (PBS) or with a SE-positive supernatant from a clinical S. aureus isolate (SA sup A) for 72h. Contour plots show gated malignant cells. cMalignant cells
(SeAx) and nonmalignant cells (MF1850) were cultured alone or in the presence of nonmalignant cells and malignant cells, respectively, with either vehicle (PBS)
or SEA for 48h. Contour plots show gated malignant cells in upper row and nonmalignant cells in bottom row.
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Primary SS cells upregulate FOXP3 after stimulation
with SE
Initially, we measured FOXP3 mRNA in PBMCs from
SS patients cultured with a pool of SEs, including SEA,
SEB, SEC2, SED, and SEI. As shown in Fig. 2a, a pool of
SEs induced a significant increase in FOXP3 mRNA
expression in primary PBMCs from SS patients. Next, we
measured FOXP3 mRNA in sorted malignant cells after
culture of PBMCs from SS patients stimulated with a pool
of SEs. Figure 2b shows that primary malignant cells did
indeed upregulate FOXP3 following co-culture with SEs
and nonmalignant cells. Supernatants from SE containing
clinical isolates also induced FOXP3 expression in pri-
mary PBMCs from three out of four SS patients (Fig. 2c).
Likewise, FOXP3 protein expression was detected in
PBMCs from three SS patients stimulated with SEA (Fig.
2d). In accordance, SEA induced FOXP3 expression in
CD25-positive malignant and nonmalignant T cells, as
judged from flow cytometry analysis of primary SS cells
(Fig. 3, upper PBS versus 0.2–0.8 ng/ml). Higher con-
centrations of SEA did not further increase the fraction of
FOXP3-positive cells. On the contrary, the fraction of
FOXP3-positive T cells gradually declined in response to
SEA concentrations above 0.8 ng/ml, suggesting that an
increased concentration did not increase a stronger
FOXP3 response in primary SS cells (Fig. 3, lover part).
FOXP3 upregulation in malignant cells is dependent on
IL-2/STAT5 signaling
Having established that malignant cells can upregulate
FOXP3 expression in response to SE if nonmalignant cells
are present, we decided to study in detail the crosstalk and
signaling pathways involved. As shown in Fig. 4a, mutations
in the MHC class II binding site of SEA (D227A and F27A)
effectively abrogated the SEA-induced FOXP3 expression,
indicating that FOXP3 expression was dependent on the
binding of SEA to MHC class II molecules. To examine
whether the SE-induced FOXP3 expression in malignant
cells in co-culture involved soluble factors and/or cell–cell
contact with nonmalignant cells, we applied monocultures
and co-cultures as above with and without inserted semi-
permeable membranes. These membranes allow exchange
of soluble factors, such as cytokines, but bar cell passage. As
shown in Fig. 4b, SEA induced comparable FOXP3
expression in malignant cells in co-culture with and without
semipermeable membranes separating them from
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Erk
SEA + + +
SS pt. #1 SS pt. #2 SS pt. #3
b)
d)
PBS SE pool
Malignant T cells
c)
a)
0
2
4
6
8
10
PBS SE pool
0
1
2
3
4
PBS SA sup A SA sup B
FO
XP
3 m
RN
A 
fol
d c
ha
ng
e
FO
XP
3 m
RN
A 
fol
d c
ha
ng
e
FO
XP
3 m
RN
A 
fol
d c
ha
ng
e
primary SS PBMCs
0.1
1
10
100 PBS
SE
*
Fig. 2 Primary SS cells upregulate FOXP3FOXP3 after stimulation with SE. a PBMCs from Sézary syndrome (SS) patients were cultured in the
presence of vehicle (PBS) or a pool of S. aureus enterotoxins (SE) (SEA, SEB, SEC2, SED, and SEI) for 24h. FOXP3 expression was determined by qPCR. In
each sample, the level of FOXP3 mRNA was normalized to that of GAPDH mRNA, and it is depicted as fold change compared to samples with PBS
with geometric mean and 95% confidence interval. Student’s t-test was applied on delta CT values, p<0.05 (n=12). b PBMCs from SS patients were
cultured in the presence of vehicle (PBS) or a pool of SE (SEA, SEB, SEC2, SED, and SEI) for 24h, and then sorted by FACS into malignant and
nonmalignant cells. FOXP3 expression was determined by qPCR. In each sample, the level of FOXP3 mRNA was normalized to that of GAPDH mRNA
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expression was determined by western blotting.
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nonmalignant cells, indicating that soluble factors are suf-
ficient in SEA-induced FOXP3 expression in malignant
cells, whereas cell–cell contact between malignant and
nonmalignant cells was not required. As we have previously
reported that SEA induced IL-2 expression by non-
malignant CD4+ T-cell lines20, we examined whether exo-
genous IL-2 or mitogenic stimuli (PMA in combination
with Ionomycin) could induce FOXP3 in primary malignant
cells. As shown in Fig. 4c, IL-2 induced FOXP3 expression
in primary malignant cells, whereas PMA and Ionomycin
did not. In accordance with the findings above, SE had no
effect on FOXP3 expression by malignant cells per se, i.e., in
the absence of nonmalignant cells. However, following co-
culture with SE and allogeneic nonmalignant cells, primary
malignant cells displayed SE-induced FOXP3 expression
(Fig. 4d). Thus, the addition of nonmalignant cells together
with SE caused strong FOXP3 upregulation in otherwise
nonresponsive primary malignant cells. Taken together
these findings suggest that SE triggered nonmalignant cells
to release soluble factors, which in turn induced FOXP3
expression in malignant cells. As SEA induced a transient
expression of IL-2 by nonmalignant T cells in our co-
culture system20, we addressed whether induction of
FOXP3 was also transient and mediated by IL-2. Accord-
ingly, co-cultures were pretreated with and without SEA for
72 h prior to extensive washing, and subsequent co-culture
for additionally up to 72 h. As shown in Fig. 4e, pretreat-
ment with SEA induced a substantial fraction of FOXP3-
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and it is depicted as fold change compared to malignant cells with PBS. d Primary SS cells and nonmalignant (MF1850) T-cell lines were either
cultured alone, co-cultured separated by transwells, or cultured together with vehicle (PBS) or a pool of SE (SEA, SEB, SEC2, SED, and SEI) for 24h. The
co-cultured malignant cells and nonmalignant cells were sorted by FACS, and the relative level of FOXP3 and GAPDH mRNA were determined in all
samples by qPCR. In each sample, the level of FOXP3 mRNA was normalized to that of GAPDH mRNA and it is depicted as fold change compared to
mono-cultured malignant cells with PBS. “Malign. transwell” signifies FOXP3 expression in malignant cells in transwell with nonmalignant cells and
vice versa for “nonmalign. transwell”. “Malign. co-cultured” signifies FOXP3 expression in malignant cells co-cultured with nonmalignant cells and vice
versa for “nonmalign. co-cultured”. e Malignant cells (SeAx) and nonmalignant (MF1850) T cells were co-cultured for 3 days in the presence of vehicle
(PBS) or SEA, and then spun down and washed three times and resuspended in fresh media. FOXP3 expression in malignant cells was analyzed by
flow cytometry after 0, 24, 48, and 72h. f Malignant cells (SeAx) and nonmalignant (MF1850) T cells were cultured together, and in the presence of
SEA and either anti-human IL-2, anti-human IL-15, a combination thereof, or isotype control. FOXP3 expression was determined by western blotting.
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positive cells (28%) compared with <1% in untreated (PBS)
controls (Fig. 4a; 0 h, left lane). Twenty-four hours after
pretreatment with SEA, the fraction of FOXP3-positive cells
increased further to above 40% (Fig. 4e, 24 h) followed by a
gradual decline to <10% FOXP3-positive malignant T cells
at 72 h (Fig. 4e, 72 h). An IL-2 neutralizing antibody
inhibited SE-induced FOXP3 expression in malignant cells
following co-culture with nonmalignant cells (Fig. 4f),
whereas an IL-15 neutralizing antibody had little effect as
judged by western blotting, which detects multiple isoforms
of FOXP3 (ref. 19).
Since FOXP3 is a well-known target of STAT5 in
malignant cells44 and STAT5 is downstream of IL-2 sig-
naling45, we investigated STAT5 activation in malignant
and nonmalignant cells cultured with and without SEA.
Figure 5a shows that SEA induced strong STAT5 activa-
tion in malignant cells following co-culture with non-
malignant cells measured by intracellular flow cytometry,
whereas SEA had no effect on STAT5 activation in
monocultures of malignant cells (Fig. 5a, upper). In con-
trast, SEA induced STAT5 activation in monocultures of
nonmalignant cells, which was largely unaffected by the
presence of malignant cells (Fig. 5b, upper). Exogenous
IL-2 induced a modest STAT5 activation in malignant
cells, which was further upregulated in co-cultures (Fig.
5a, lower). IL-2 also induced Stat5 activation in non-
malignant cells—irrespective whether malignant cells
were present in the culture (Fig. 5b, lower). siRNA-
mediated knockdown of STAT5 in malignant cells
decreased FOXP3 expression by roughly 50% (Fig. 5c),
confirming previous data that FOXP3 transcription is at
least partly mediated by STAT5 in malignant cells19.
Discussion
Here, we show that SE-positive supernatants from S.
aureus CTCL skin isolates, as well as SE can induce
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Fig. 5 FOXP3 upregulation depends on IL-2/STAT5 signaling. a Malignant cells (SeAx) were cultured alone or together with nonmalignant cells
(MF1850), and in the presence of vehicle (PBS) or S. aureus enterotoxin A (SEA) with and without exogenous IL-2 for 48h. pY-STAT5 was determined
by flow cytometry. b Nonmalignant cells (MF1850) were cultured alone or together with malignant cells (SeAx), and in the presence of vehicle (PBS)
or SEA with and without exogenous IL-2 for 48h. pY-STAT5 was determined by flow cytometry. c Malignant cells (SeAx) were treated with
nontargeting siRNA control or siRNA targeting STAT5, and cultured with nonmalignant (MF1850) in the presence of SEA. FOXP3 expression was
determined by qPCR. FOXP3 mRNA was normalized to that of GAPDH mRNA and it is depicted as fold change compared to nontargeting siRNA
control.
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expression of FOXP3 in both primary malignant cells and
in an immortalized patient-derived T-cell line, when
cultured in the presence of nonmalignant cells. Since
malignant cells alone were largely unresponsive to SE, our
findings indicate that induction of FOXP3 expression in
malignant cells is indirect and mediated by signals derived
from nonmalignant cells. In support, transwell experi-
ments showed that soluble factors were involved, whereas
direct cell–cell contact between malignant and non-
malignant cells was not required for SE-induced FOXP3
expression in malignant cells. IL-2 is a well-established
inducer of FOXP3 in T cells46 and importantly, blockage
of IL-2 by neutralizing antibodies strongly inhibited
FOXP3 induction by SE in co-cultures. STAT5 is an IL-2-
activated transcription factor involved in induction of
FOXP3 expression44. In accordance, siRNA-mediated
knockdown of STAT5 inhibited SE-induced FOXP3
expression by malignant cells in co-cultures. Collectively
these findings support a model20,38, where SE induces
nonmalignant cells to produce and release IL-2, as well as
other soluble factors that in turn upregulate FOXP3
expression in malignant cells. This model implies that
nonmalignant cells can respond to SE, which was indeed
the case as seen in monocultures of nonmalignant cells.
It may come as a surprise, that nonmalignant cells
respond directly to SE, since it is well known that SE
stimulation of murine T cells (expressing an appropriate
T cell receptor (TCR) Vβ chain) depends on the presence
of MHC class II-positive antigen-presenting cells (APCs).
In contrast to murine T cells, however, human T cells
express MHC class II molecules upon activation47.
Moreover, nonmalignant cells lines from CTCL patients
and CD4 T-cell lines from healthy individuals con-
stitutively express MHC class II molecules48 and are able
to present SE to other T cells48. MHC class II expressing
T cells respond to very low concentrations of SE. In
accordance, mutations in the MHC class II binding site of
SEA abrogated the ability to induce FOXP3 expression in
malignant cells in co-cultures. As MHC class II molecules
also function as signaling molecules capable of inducing
tyrosine kinase activity, activation of PLC-γ, and expres-
sion of IL-2 receptors in co-activated human T cells49, it is
possible that MHC class II and TCR act synergistically in
SE-mediated activation of nonmalignant cells. In contrast
to cultures of malignant and nonmalignant cell lines,
primary PBMC cultures from healthy individuals contain
MHC class II-positive APCs, such as dendritic cells,
monocytes, and B cells, all of which are able to present SE
to T cells. Although the numbers of these cell types are
often reduced to a varying degree in SS patients, it is likely
that APCs in PBMC cultures from SS patients contribute
to SE presentation, because even small numbers of APCs
are highly potent to present SE to T cells50. We suspect
that this may also account for some of the variation in
SE-mediated activation of malignant cells, as the number
of cells that are able to present SE must vary between SS
patients with different tumor loads.
Since the original findings by Berger and colleagues that
CTCL involved malignant proliferation of Treg cells,
several studies have investigated whether or not malig-
nant cells displayed a FOXP3+ (refs. 19,24–29) phenotype in
peripheral blood of SS patients. Using different methods
and cohorts of patients, investigators have come to very
different conclusions. For instance Klemke et al. only
detected FOXP3+ T cells in a minority of patients, but
with a bimodal expression pattern, i.e., some patients
displayed high numbers of FOXP3+ T cells, while others
had reduced numbers compared to controls25. In contrast,
Capriotti et al. reported that PBMCs from 30% of SS
patients expressed FOXP3 and interestingly, that those
patients with FOXP3 expression had a significantly worse
prognosis than patients without26. In accordance, our
group has found that the malignant cells from 8 out of 15
SS patients stained positive for FOXP3 (ref. 19). Heid et al.
obtained comparable results27, whereas several others
reported on reduced or completely lacking expression of
FOXP3 in SS patients compared to healthy donors24,28,29.
Kasprzycka et al.17 obtained evidence of a heterogeneous
FOXP3 expression in malignant cells in lesional skin and
proposed a hypothesis, where cytokines in the tumor
microenvironment drive the heterogeneous FOXP3
expression in malignant cells17. Since the majority of SS
patients with advanced disease have a colonization or
infection of their skin with SE-producing S. aureus51,
and SE induce FOXP3 expression in malignant cells
as shown here in vitro, it is likely that SE may also
induce FOXP3 expression in vivo through induction of
cytokine expression by nonmalignant cells in the tumor
microenvironment.
Accordingly, differences in FOXP3 expression by
malignant cells between SS patients and cohorts of
patients may reflect differences in skin colonization and
infection with SE-producing S. aureus. This mechanism
also provides a possible explanation for some of the dis-
ease heterogeneity between SS patients and within indi-
vidual SS patients11,30,52,53, as well the reported
discrepancies between different cohorts of patients. If
confirmed in independent cohorts, enhanced FOXP3
expression by malignant T cells may have potential as a
marker of infection-induced immune deregulation.
Moreover, we believe that our findings lend support to a
clinical rationale for aggressively treating S. aureus
infections in selected SS patients, in order to dampen
inflammation and limit any potential immune-regulatory
effects exerted by activated malignant T cells.
In conclusion, we show for the first time ever that S.
aureus SE can induce FOXP3 expression in malignant
cells obtained from SS patients. Therefore, we propose
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that SE-producing S. aureus in the tumor microenviron-
ment modulate the phenotype of malignant cells in vivo.
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